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ABSTRACT: Matrix metalloproteinases (MMPs) are central to cancer development and metastasis. They are highly active in the 
tumour environment and absent or inactive in normal tissues; therefore they represent viable targets for cancer drug discovery. In 
this study we evaluated in silico docking to develop MMP-subtype-selective tumour-activated prodrugs. Proof of principle for this 
therapeutic approach was demonstrated in vitro against an aggressive human glioma model, with involvement of MMPs confirmed 
using pharmacological inhibition.  
 
 
INTRODUCTION 
Matrix Metalloproteinases (MMPs) are zinc-dependent en-
doproteases central to digestion of extracellular matrix (ECM) 
and pericellular proteins involved in regulation of many nor-
mal physiological processes including tissue growth and em-
bryogenesis.1-5 Their activity is regulated by both post-
secretion zymogenic activation and inhibition by endogenous 
inhibitors termed TIMPs (tissue inhibitor of metalloprotein-
ase).6 However, dysregulation of MMP expression and unbal-
anced endoproteolytic activity of specific MMPs are a major 
contributor to many degradative diseases including arthritis, 
cancer, cardiovascular disease, inflammatory disorders, and 
neurodegeneration,5,7-9 thus making them attractive drug tar-
gets.2, 10, 11  
In the last two decades significant drug discovery effort was 
focused on inhibition of MMPs as a strategy to prevent tumour 
invasion and subsequent tumour metastases.12 As a result the 
pharmaceutical industry produced a number of well tolerated 
orally active MMP inhibitors (MMPi).13 These agents were 
largely peptidomimetic zinc-binding hydroxamates, based 
upon an MMP peptide substrate.2,14,15 Although many of these 
inhibitors progressed to late stage clinical trials against meta-
static cancer, limited clinical success was seen due to a lack of 
inhibitor MMP-subtype specificity and insufficient knowledge 
about the complexity of the disease biology.2,16,17 Several addi-
tional strategies have been evaluated over recent years, includ-
ing development of inhibitors exploiting the enzymatic transi-
tion state,2,18 inhibitors binding enzyme cavity subsites,19 or 
alternative zinc chelation groups.2 Generation of MMP sub-
family-selective inhibitors still proves mostly elusive however, 
because of the broad structural similarity of their active site, 
substrate complexity, and identification of specific MMPs as 
anti-targets.2,17 
In contrast to inhibition of MMP function, exploitation of 
the MMP-mediated proteolysis within diseased tissues has 
also been investigated as a diagnostic and prognostic ap-
proach. These studies used activity-based probes comprising a 
‘broad-spectrum’ or selective MMP-cleavable peptide labelled 
with a quenched fluorophore or imaging moiety.20,21 In this 
approach, elevated MMP activity in the diseased tissue results 
in activation of the probe via selective cleavage of the peptide 
and release of the contrast agent, facilitating imaging and 
quantification of MMP activity.20,21  
In line with the MMP-activated probe-based approaches, el-
evated activity of MMPs within diseased tissue has also been 
explored as a strategy for conversion of a non-toxic peptide-
conjugated prodrug into a potent therapeutic entity within the 
disease site. The advantage of this approach is dose intensifi-
cation and reduced systemic drug exposure.1,22-26 A require-
ment for success in activity-probes, prodrugs, or theranostic 
approaches is MMP-selectivity through incorporation of 
MMP-subtype unique (e.g. MMP-2, MMP-9 or MMP-14) 
peptide sequences and subsequent disease-selective activation. 
The rationale for this study is to exploit the MMP binding 
subsites and modify the substrate residues to produce a pro-
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drug selective for MMP-2 over MMP-9 and MMP-14, and 
create a robust approach which could be exploited for devel-
opment of endoprotease-activated diagnostic probes and ther-
apeutics. Visualizing and quantifying binding preferences and 
motifs can provide valuable insight into the structural deter-
minants of substrate selectivity and enable MMP-targeted drug 
development.27 In order to achieve this the following steps 
were undertaken; definition of the catalytic domains within the 
relevant MMPs through in silico study, docking of known 
MMP-selective sequences to highlight key catalytic binding 
determinants, subsequent rational design of novel MMP-
selective prodrugs, and in vitro confirmation of MMP-
selectivity and therapeutic proof-of-concept. In this work a 
reiterative approach using in silico proteolytic docking cou-
pled to in vitro biochemical assessment has been applied to 
enable the development of prodrugs that are selectively acti-
vated by MMP-2 over MMP-9, the closely related gelatinase 
family members; and over MMP-14 – the endogenous activa-
tor of MMP-2. The availability of three-dimensional crystal 
structures of MMPs allowed us to critically examine the dif-
ferences existing between the catalytic domains of the MMP-2 
(PDB ID: 1QIB), MMP-9 (PDB ID ID: 1GKC) and MMP-14 
(PDB ID: 1BQQ).28,29,30 This allowed for successful develop-
ment of in silico models of MMPs. The in silico model was 
able to accurately predict known cleavage sites on substrates 
and prodrugs by MMPs, thus enabling rationalized design of 
an MMP-2 selective peptide.  
RESULTS AND DISCUSSION 
The catalytic domain of MMPs consists of five β-sheet 
strands and three α-helixes. The catalytic centre comprises of a 
catalytic zinc ion coordinated by three histidine residues and a 
glutamic acid.28 The specificity loop within the catalytic site of 
MMPs shows the largest structural differences, as visualized 
for MMP-2 and MMP-9 in Figure S1. The overall folding of 
MMP-2 and MMP-9 resembles those of other MMPs, which is 
expected based on their structural similarity (Figure S1).31 The 
cavity of S1’ pockets in MMPs is well-suited to accommodate 
a wide-range of hydrophobic residues, with the main function-
al difference between MMP subtypes lying in this region. In 
MMP-9, residues 421–423 form the wall of the binding pocket 
and the specificity loop is formed by the residues 424 – 430. 
Arg424 is present at the bottom of S1’ pocket and closes off 
the end. Arg424 is therefore responsible for making the pocket 
cavity smaller in MMP-9 than in MMP2 (Figure S1). Whereas 
in MMP-2, the external wall of the S1’ pocket is largely 
formed by Thr227–Phe232 specificity residues, creating a 
deeper pocket. These differences can potentially be exploited 
for rational design of MMP-selective substrates/conjugates. 
To probe the selective binding of potential substrates the 
peptide sequence of the non-specific gelatinase substrate 1 
Dnp-Pro-β-cyclohexyl-Ala-Gly-Cys(Me)-His-Ala-Lys(N-Me-
Abz)-NH2 (M-2055)
32 was input into BIOVIA Discovery Stu-
dio 4.0, minimized with respect to its geometry, and then 
docked into the MMPs. In order to validate modelling work, 
attempts at crystallization of this and other substrates were 
undertaken in order to determine the X-ray crystal structure. 
Crystallization experiments failed to yield suitable crystals for 
structure determination, therefore only force field 
(CHARMM) minimized geometries of the substrates were 
employed throughout this study.  
Figure 1 shows the interaction of 1 peptide sequence with 
human MMP-2 and MMP-9. In both MMPs the zinc ion inter-
acts with the Gly and Cys(Me) bond, the known cleavage site 
according to Bickett et al.32  MMP-9 is able to bind tightly 
with the substrate residues compared to MMP-2, as deter-
mined by differences in their predicted inter-atomic zinc dis-
tances and overall binding energies. The substrate bound 
MMP-complexes provided crucial insight into the differences 
in their subsite interactions, as S1 and S3 subsites in MMP-2 
demonstrated affinity to accommodate longer side-chains than 
MMP-9. The charged nature of the S2 subsite (presence of 
His205) in MMP-2 lends affinity for acidic residues, whereas 
this feature is not observed in MMP-9. In the MMP-9 struc-
ture, the carboxylic acid between Gly and Cys(Me) chelates 
the zinc ion (2.1 Å) and is involved in a strong H-bond to the 
carboxylate O of Glu402. The zinc ion is further coordinated 
by three Histidine residues namely His401, His405 and 
His411 present in Helix αβ segment of the protein. Only the 
P1’ amino acid is involved in strong H-bonds with Arg424 
(2.2 Å), which creates the wall-forming segment.  The strong 
binding of Arg424 with the P1’ residue is an important deter-
minant of the specificity pocket. Remaining substrate residues 
are involved in strong interactions with the bulge-edge seg-
ment molecules (Gly186 to His190) with interatomic distances 
ranging from 2.5 to 3.1 Å. The docked complex of 1 and 
MMP-9 has an overall binding energy of 706 kcal/mol (Fig-
ures 1,S2, S3 and S4). 
Consideration of the interaction of 1 with the active site of 
MMP-2 shows a marked reduction in affinity in energetic 
terms, the predicted interaction is seven times weaker than that 
of 1 and MMP-9 (binding energy of 101 kcal/mol). Gly forms 
the P1 subsite and Cys(Me) forms the P1’ subsite and the 
presence of a zinc ion, chelated by the carboxylic acid be-
tween P1-P1’ residues (3.8 Å), further confirms this. The P1’ 
residue, although favourable for the MMP-2 specificity 
 
Figure 1. (Top) Stereo view of the docked complexes of 1 sub-
strate and the catalytic domain of human MMP-2 (PDB ID: 
1QIB) and MMP-9 (PDB ID: 1GKC). The MMP-substrate 
docked complexes are merged with zinc as the same point of 
view. MMP-2 structure is shown in red, zinc as purple and 1 sub-
strate (white sticks) docked within MMP-2 active site. MMP-9 is 
shown in grey, zinc as green and 1 substrate (thin green sticks) 
docked within its active site. (Bottom) Schematic representation 
of 1: active site binding interaction in human MMP-2 and MMP-
9. MMP-2 and MMP-9 enzyme binding pockets are shown in red 
and green respectively. Substrate chemical structure and its scis-
sile bond is shown in black. The zinc ion is indicated in blue.  
Page 2 of 12
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 3 
 
 
pocket, is not involved in any significant interaction with 
MMP-2 residues. The remaining substrate residues have weak 
H-bond interactions with wall-forming and bulge-edge seg-
ments of MMP-2 with interatomic distances ranging from 3.1 
to 5.1 Å. This is expected as 1 residues are oriented away from 
further MMP-2 binding pockets (Figure 1, S2, S3 and S4). 
Key observed differences between the binding affinity of 
MMP-2 and MMP-9 with 1 are: S1 and S3 subsites in MMP-2 
can accommodate longer side-chains than MMP-9. Charged 
nature of S2 subsite in MMP-2 has affinity for acidic residues, 
whereas this feature is not observed in MMP-9. Refer to figure 
S5 for in silico binding of 1 with the active site of MMP-14, 
also demonstrating zinc interaction between Gly-Cys(Me) 
bond. 
To experimentally validate the predictability of this model, 
and confirm the in vitro cleavage position of 1, hydrolysis of 
the substrate by recombinant MMP-2 and MMP-9 was as-
sessed over a 12 hour period.  The resultant products were 
analysed by LCMS using a reverse phase gradient system to 
separate the substrate 1 and proteolytic products. The identifi-
cation of these species was confirmed by retention time and 
mass spectrometry (MS) data. 1 demonstrated a retention time 
(tR) of 2.8 minutes (Figure S6) and rapid cleavage  by MMP-9 
at Gly-Cys(Me) bond was confirmed by LCMS, two peaks 
corresponding to Dnp-Pro-β-Cyclohexyl-Ala-Gly at tR of 2.3 
minutes (m/z 491.5Da, [M+H]+) and Cys(Me)-His-Ala-
Lys(N-Me-Abz)-NH2 at tR of 2.47 minutes (m/z 604.7Da, 
[M+H]+) (Figures 2 and S7). Slow hydrolysis of 1 by MMP-2 
(compared to MMP 9) at Gly-Cys(Me) bond was confirmed 
by two peaks at tR of 2.3 minutes and tR of 2.47 minutes. 
MMP-2 cleavage experiments displayed a parent peak of 1, 
detected at tR of 2.8 minutes (m/z 1077.5Da, [M+H]+), sug-
gesting that MMP-2 metabolised 1 at a slower rate than MMP-
9 (Figures 2 and S8). Recombinant MMP-14 also cleaved 1 at 
the Gly-Cys(Me), confirming the in silico prediction (Figure 
S9). This in vitro assessment supports the validity of the pre-
dicted in silico model of substrate and MMP interactions and 
was subsequently used for further design of MMP-targeted 
therapeutics. 
      
 
Figure 2. Schematic representation of the cleavage of 1 substrate 
by recombinant MMP-2 and MMP-9 enzymes at Gly-Cys(Me).  
 
The next phase of the study was to design a prodrug (sub-
strate and warhead) which would be selectively activated by a 
specific MMP over a close family homologue i.e. cleaved by 
MMP-2 and not by MMP-9 or MMP-14. A known MMP-
targeted peptide-conjugated doxorubicin prodrug33,34 was eval-
uated as it is cleaved by MMP-2, MMP-9 and MMP-14, pre-
senting an excellent model for further modification. MMP-
targeted peptide-conjugates were synthesized via solid phase 
chemistry and purified by reverse phase HPLC, the chemo-
therapeutic drug doxorubicin conjugated to the C-terminus 
(Scheme S10). In silico interaction of the 2 (reference com-
pound) with MMP-2 and MMP-9 shows the zinc ions are che-
lated by the carboxylate between Gly-Ser(O-Benzyl) bond 
(2.6 Å and 2.8 Å respectively), the known cleavage site.31,32 
Figure S11 shows the binding pockets of MMP-2 are larger 
and deeper than MMP-9, S1 subsite allowing for larger aro-
matic residues. The compound 2 aligns tightly into the active 
site of both MMPs as shown by their predicted interatomic 
zinc distances and binding energies (555 kcal/mol and 492 
kcal/mol) in MMP-2 and MMP-9 docked complexes respec-
tively. Active site residues interact with the compound in a 
similar way to that previously explained. His205 in MMP-2 
αβ-Helix loop makes the S2 pocket charged in nature and 
could potentially accommodate acidic residues (Figures S11 
and S12). Similar to MMP-2 and MMP-9, MMP-14 also 
demonstrated selective interaction with 2 (Figure S13) To 
experimentally validate the in silico docking of 233,34 and con-
firm the in vitro cleavage site, the lysis of this prodrug by re-
combinant MMP-2 and MMP-9 was assessed over a 12 hour 
period; with the resultant products being assessed by LCMS. 
HPLC (reverse phase gradient) was used to separate 2 (Cbz-
Glu-Pro-Leu-Gly-Ser(O-Benzyl)-Tyr-Leu-Doxorubicin),33,34 
identification confirmed by mass spectrometry (MS) with a 
retention time (tR) of 3.63 minutes (Figure S14). Cleavage of 
2 by both MMP-2 and MMP-9 at Gly-Ser(O-Benzyl) bond 
was confirmed by LCMS, two peaks corresponding to Cbz-
Glu-Pro-Leu-Gly at tR of 2.87 minutes (m/z 547.2Da, 
[M+H]+) and Ser(O-Benzyl)-Tyr-Leu-Doxorubicin at tR of 
3.23 minutes (m/z 997.4, [M+H]+). (Figures 3, S15 and S16). 
A parent peak was also detected at tR of 3.63 minutes (m/z 
1525.8Da, [M+H]+). Similarly, MMP-14 also displayed hy-
drolysis of 2 at the Gly-Ser(O-Benzyl) bond (Figure S17). 
This in vitro assessment supports the predictability of in silico 
model of anticancer therapeutics with MMPs, for further de-
sign of MMP-2 selective prodrugs.  
 
 
Figure 3. Schematic representation of the cleavage of 2 by re-
combinant MMP-2 and MMP-9 enzymes at the Gly-Ser(O-Bn) 
bond. 
 
Rational design of a peptide conjugate selective for MMP-2 
over MMP-9 was achieved by incorporating residues into the 
peptide chain to fit S1, S2, S3 and S1’ pockets of MMP-2 
which differ in size and polar affinity compared to MMP-9. 
The following modifications were incorporated: Aromatic 
residues in S1 subsite; acidic side-chain in S2 subsite and a 
polar side-chain at the S3 subsite. Small non-polar residues 
were included at the S1’ subsite despite S1’s potential to ac-
commodate longer hydrophobic residues. This was due to 
longer residues leading to a negative effect on the predicted 
binding affinity, due to conformational alteration.  
A B
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Figure 4. (Left) Stereo view of docked complexes of 3 (white 
sticks), catalytic domain of human MMP-2 (PDB ID: 1QIB) 
(Red) and MMP-9 (PDB ID: 1GKC) (Green). Catalytic and struc-
tural zinc ions are shown as purple spheres and active-site cleft 
residues (αβ-helix loop and the specificity loop) are shown as 
green. (Right) Schematic representation of 3 substrate: active site 
binding interaction in MMP-2 and MMP-9, are shown in red and 
green respectively. Substrate chemical structure and its scissile 
bond is shown in black and zinc ion coordinated by histidine is 
indicated in blue.  
  
The zinc ion in MMP-2 demonstrated interaction with 3 at 
carboxylate between Homophenylalanine (Hof)-Leu bond (1.9 
Å), indicating the predicted cleavage site. Residues of MMP-2 
tightly bind with 3 as demonstrated by strong interactions with 
the bulge-edge segment molecules (Gly162 to His166) and the 
wall-forming segment molecules (Tyr223 to Thr229) with 
interatomic distances ranging from 1.8 to 2.8 Å. The docked 
complex of 3 and MMP-2 has an overall binding energy of 
805 kcal/mol. In MMP-9 the zinc interaction is not detectable 
and the predicted binding energy is negative (-107 kcal/mol) 
suggesting the modified peptide residues should give selectivi-
ty of MMP-2 over MMP-9 (Figures 4, S18 and S19). Similar-
ly, based on the peptide modifications for MMP-14 selectivity 
suggested in the literature,35,36 the zinc interaction between 3 
and MMP-14 was non-detectable and the binding energy was 
negative (Figure S20). The hydrolysis of 3 by recombinant 
MMP-2, MMP-9 and MMP-14 was assessed over a 12 hour 
period and analyzed by LCMS. Reverse phase HPLC identi-
fied 3 at tR of 3.58 minutes (Figure S21). 3 was preferentially 
cleaved by MMP-2 at Hof-Leu and two peaks were identified; 
corresponding to Leu-Doxorubicin at tR of 2.078 minutes (m/z 
657.2Da, [M+H]+) and Cbz-Gly-Pro-Ile-Gln-Glu-Hof at tR of 
2.826 minutes (m/z 821.4Da, [M+H]+) (Figures S22 and S23). 
Conversely MMP-9 and MMP-14 did not cleave 3 in the same 
timeframe, indicating that 3 is MMP-2 selective supporting the 
in silico prediction (Figure S22 and S24).  
In order to assess activity and demonstrate proof-of-concept 
for the developing approach, the effects of 3 were assessed 
against the U87-MG malignant human glioma cell line. This 
cell line is derived from a highly aggressive glioma tumour 
and expresses both MMP-2 and MMP-9 (Figure 5). Cytotoxi-
city was observed in this cell line with doxorubicin, Leucine-
doxorubicin (Leu-Dox) and 3, with IC50 values of 0.3±0.2 
µM, 0.6±0.2 µM and 5.0±1.2 µM, respectively. The differen-
tial cytotoxicity between doxorubicin and 3 supports the re-
quirement for 3 to be activated prior to inducing its effects. 
Furthermore, 3 remained inactive in the presence of a pan-
MMP inhibitor, (2R)-N'-hydroxy-N-[(2S)-3-(1H-indol-3-yl)-
1-(methylamino)-1-oxopropan-2-yl]-2-(2-
methylpropyl)butanediamide (GM6001; Ilomastat/Galardin),37 
demonstrating MMP-selective chemotherapeutic action of this 
prodrug. 
In order to further determine the tumour-selective activation 
of 3, its metabolism was studied ex vivo using MMP-
expressing HT1080 human tumour xenograft33, mouse plasma 
and homogenized murine liver and kidney tissues (Figure 
S25). Rapid metabolism of 3 was observed in the HT1080 
xenograft homogenate (t½ = > 8.8 minutes). In comparison, 3 
was relatively stable in plasma (t½ = significantly > 90 
minutes), murine liver (t½ = > 17.0 minutes) and murine kid-
ney (t½ = > 38.1 minutes).  The liver homogenate is a ‘worse 
case scenario’ for 3’s stability due to a high proportion of both 
extracelluar and intracellular proteases. 3 displayed relative 
stability in mouse plasma and liver and kidney homogenates, 
and associated rapid metabolism in tumour homogenates.  
  
 
 
Figure 5. Therapeutic activity of 3 against human cancer. A) 
Expression of MMP-2 and MMP-9 mRNA in the U87-MG glio-
ma cell line; B) MMP-activity in the U87-MG cell line, as 
demonstrated by activation of 1 substrate Dnp-Pro-β-cyclohexyl-
Ala-Gly-Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH2; C) Cytotoxicity 
of doxorubicin, Leu-Dox and 3 against U87-MG cell line. MMP-
selective activation of 3 in the presence of a pan-MMP inhibitor 
(Ilomastat).  
CONCLUSIONS 
Targeted cancer therapies offer the potential of reduced side 
effects along with benefits of prolonging drug exposure to 
cancerous tissues, enabling improved tumour response and 
survival rates.38,39 Harnessing the elevated enzymatic activity 
of MMPs within the tumour microenvironment to selectively 
convert a non-toxic prodrug into a potent chemotherapeutic 
agent is one such approach with significant potential therapeu-
tic scope.40,41 In this study a reiterative approach using in silico 
docking coupled to in vitro biochemical proteolytic assess-
ment have been applied to enable the development of anti-
cancer prodrugs selectively activated by MMP-2, but not by 
close family homologue-MMP-9 or the MMP-2 activator  
MMP-14. Proof-of-concept for this therapeutic approach was 
demonstrated against a glioma cell line in vitro, with the in-
volvement of MMPs confirmed using pharmacological inhibi-
tion and by tumour-selective activation with ex vivo tumour 
xenografts. This study has shown that it is feasible to utilise in 
silico predictive approaches to rationally design MMP-
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selective prodrugs with possible utility in the treatment of 
cancer.  
EXPERIMENTAL 
3D-Molecular Modelling 
Refer to Method S30 
 
Synthesis of MMP-targeted peptide conjugates 
Custom designed peptide sequences with Cbz (Ben-
zyloxycarbonyl) as the chemical endcap were supplied 
(Bachem, Switzerland)/ synthesised using solid phase strategy. 
Activation of the pre-loaded 2-chlorotrityl resin was carried 
out in a fritted polypropylene reaction chamber. 0.1mmol of 
resin was weighed into the reaction chamber and 2 ml of dry 
DCM added. The reaction vessel was shaken for 45 minutes. 
After this time, DCM removed and the resin washed further 
with DCM. Single couplings were carried out using 5 equiva-
lents of peptide (compared to resin), 5 equivalents of benzotri-
azol-1-yloxytripyrrolidinophosphonium hexafluorophosphate 
(PyBOP®), 10 equivalents of N,N-Diisopropylethylamine 
(DIPEA) and 2 ml of DMF under agitation for 45 minutes. 
Double peptide couplings were carried out- 2 x 45 minute 
couplings for each residue addition- the reaction drained after 
each coupling and fresh reagents added. After each set of cou-
pling reactions, the reaction solution was drained and resin 
washed with 5 portions of 2 ml DMF. Removal of the Fmoc 
group was carried out using 5 ml of a solution of 20% piperi-
dine in DMF for 5 under agitation. Piperidine solution was 
drained and fresh solution added for a further 10 minutes un-
der agitation. Piperidine solution was drained and the resin 
rinsed using 5 portions of 2 ml DMF. Peptide-resin was treat-
ed with a solution of 20% hexafluoroisopropanol in DCM for 
1 hour. The resin was removed by filtration and the solvent 
removed from the filtrate under reduced pressure before pre-
cipitation using ether and decanting of the liquid (followed by 
subsequent ether washes). The resulting solid peptide (Cbz-
GPIQ(Trt)-E(tBu)-hPhe-L-OH) was dissolved in deionized 
water and acetonitrile mix and lyophilized. Purification of 
peptides was carried out using Perking Elmer HPLC. Samples 
were injected into a column and a gradient of 0-100% solvent 
B (solvent A= 95% H2O, 5% MeCN, 0.01% TFA, solvent B = 
95% MeCN, 5%H2O, 0.01% TFA) over 95 minutes with a 
flow rate of 2.0 ml/min. Doxorubicin was conjugated to the 
peptide C-terminus as follows: Doxorubicin.HCl (0.0012 g, 
0.002 mol, 1 equiv.), peptide (0.0022 g, 0.002 mol, 1 equiv.), 
PyBOP® (0.0015 g, 0.003 mol, 1.3 equiv.), and hydroxyben-
zotriazole hydrate (0.0073 g, 0.0054 mol, 2.6 equiv.) were 
added together under nitrogen in anhydrous DMF (2 mL). 
DIPEA (8 equiv., 0.016 mol) was added and the reaction mix-
ture was stirred overnight in the absence of light. Solvent was 
removed in vacuo and the mixture triturated with cold Et2O (5 
mL) to precipitate the crude peptide which was then obtained 
through centrifugation to obtain the crude solid peptide conju-
gate. The product was then purified using a C18 column and 
reverse phase HPLC (H2O/MeCN) gradient system using  
mass spectrometry as confirmation of molecular mass to give 
a pale red solid (0.0021 g, 70 % yield). 
Liquid Chromatography and Mass Spectrometry (LCMS) de-
tection of substrates 
LC conditions: High-purity HPLC-grade solvents (Sigma-
Aldrich), analytical grade chemicals (Sigma-Aldrich) and tri-
ple distilled water were used throughout. Reverse-phase 
chromatographic separation of substrates was performed using 
an Acquity UPLC comprising a BEH C18 1.7µM column 
(2.1mm x 100mm) (Waters, UK).Mobile phases were as fol-
lows: Mobile Phase A consisted of 90% HPLC grade water, 
10% HPLC grade MeCN and 0.1% HCO2H. Mobile phase B 
consisted of 40% HPLC grade water, 60% MeCN and 0.1% 
HCO2H. 
MS conditions: A Micromass ZMD single quadrupole elec-
trospray MS was used in positive mode (Micromass, Man-
chester, UK) and MassLynx software was used to identify 
substrates and anticipated metabolites. MS source parameters 
were optimised to: desolvation gas 375 L/hr, cone gas 33 L/hr, 
capillary 2.9 kV, sample cone 16V, extraction cone 5V, fR 
lens 0.1V, source block temperature 150°C and desolvation 
temperature 200°C. Parent compounds and metabolites were 
detected as singularly charged ions using selected ion readings 
(SIR). 
 
Cleavage of substrates by recombinant MMPs 
Refer to Method S31 
 
Determination of MMP mRNA expression by semi-
quantitative RT-PCR analysis 
Refer to Method S32. 
 
MTT assay 
Refer to Method S33 
 
Metabolism of 3 in tissues ex vivo 
Refer to Method S34 
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ABBREVIATIONS AND ACRONYMS 
DCM Dichloromethane 
DIPEA N,N-Diisopropylethylamine 
DMF Dimethylformamide 
Et2O Diethyl Ether 
HCO2H Formic Acid 
HPLC High Performance Liquid Chromatography 
HT1080 Human Fibrosarcoma 
LCMS 
Liquid Chromatography - Mass Spectrome-
try 
MeCN Acetonitrile 
MMPs Matrix Metalloproteases 
MTT 
3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium Bromide 
PyBOP 
benzotriazol-1-
yloxytripyrrolidinophosphonium hexafluor-
ophosphate 
TFA Trifluoroacetic Acid 
U87-MG Human Malignant Glioma 
REFERENCES 
1. Atkinson, J. M.; Siller, C. S.; and Gill, J. H.  Tumour endoproteas-
es: the cutting edge of cancer drug delivery?, Br. J. Pharmacol. 2008 
153, 1344-1352. 
2. Vandenbroucke, R. E.; and Libert, C.  Is there new hope for thera-
peutic matrix metalloproteinase inhibition?, Nat. Rev. Drug. Discov. 
2014 13, 904-927. 
3. Brown, P. D.  Matrix metalloproteinase inhibitors in the treatment 
of cancer, Med. Oncol. 1997 14, 1-10. 
4. Bourboulia, D.; and Stetler-Stevenson W. G.  Matrix metallopro-
teinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): 
Positive and negative regulators in tumor cell adhesion, Sem. Cancer 
Biol. 2010 20, 161-168. 
5. Khokha, R.; Murthy, A.; and Weiss, A.  Metalloproteinases and 
their natural inhibitors in inflammation and immunity, Nat. Rev. Im-
munol. 2013 13, 649-665. 
6. Visse, R.; and Nagase, H.  Matrix metalloproteinases and tissue 
inhibitors of metalloproteinases: structure, function, and biochemis-
try, Circ. Res. 2003 92, 827-839. 
7. Clark, I. A.; Swingler, T. E.; Sampieri, C. L.; and Edwards, D. R.  
The regulation of matrix metalloproteinases and their inhibitors, Int. 
J. Biochem. Cell Biol. 2008 40, 1362-1378. 
8. Nagase, H.; Visse, R.; and Murphy, G.  Structure and function of 
matrix metalloproteinases and TIMPs, Cardiovasc. Res. 2006 69, 
562-573. 
9. Shay, G.; Lynch, C. C.; and Fingleton, B.  Moving targets: Emerg-
ing roles for MMPs in cancer progression and metastasis, Matrix Biol. 
: J. Int. Soc. Matrix Biol. 2015 44-46, 200-206. 
10. Hu, J.; Van den Steen, P. E.; Sang, Q. X.; and Opdenakker, G.  
Matrix metalloproteinase inhibitors as therapy for inflammatory and 
vascular diseases, Nat. Rev. Drug Discov. 2007  6, 480-498. 
11. Pirard, B. Insight into the structural determinants for selective 
inhibition of matrix metalloproteinases, Drug Discov. Today 2007 12, 
640-646. 
12. Overall, C. M.; and Kleifeld, O. Tumour microenvironment - 
opinion: validating matrix metalloproteinases as drug targets and anti-
targets for cancer therapy, Nat. Rev. Cancer 2006 6, 227-239. 
13. Mccullagh, K.; Wadsworth, H.; and Hann, M.  Carboxyalkyl 
peptide derivatives, Google Patents, EP 0126974 A1  1985. 
14. De, B.; Natchus, M. G.; Cheng, M., Pikul, S.; Almstead, N. G.; 
Taiwo, Y. O.; Snider, C. E., Chen, L.; Barnett, B., Gu, F.; and Dowty, 
M.  The next generation of MMP inhibitors. Design and synthesis, 
Ann. N. Y. Acad. Sci. 1999 878, 40-60. 
15. Overall, C. M.; and Kleifeld, O. Towards third generation matrix 
metalloproteinase inhibitors for cancer therapy, Br. J. Cancer 2006 
94, 941-946. 
16. Coussens, L. M.; Fingleton, B.; and Matrisian, L. M. Cancer ther-
apy - Matrix metalloproteinase inhibitors and cancer: Trials and tribu-
lations, Science 2002 295, 2387-2392. 
17. Dufour, A.; and Overall, C. M. Missing the target: matrix metal-
loproteinase antitargets in inflammation and cancer, Trends Pharma-
col. Sci. 2013 34, 233-242. 
18. Georgiadis, D.; and Dive, V. Phosphinic peptides as potent inhibi-
tors of zinc-metalloproteases, Top. Curr. Chem. 2015 360, 1-38. 
19. Jacobsen, J. A.; Major Jourden, J. L.; Miller, M. T.; and Cohen, S. 
M. To bind zinc or not to bind zinc: an examination of innovative 
approaches to improved metalloproteinase inhibition, Biochim. Bio-
phys. Acta 2010 1803, 72-94. 
20. Heal, W. P.; Wickramasinghe, S. R.; and Tate, E. W. Activity 
based chemical proteomics: profiling proteases as drug targets, Curr. 
Drug Discov. Technol. 2008 5, 200-212. 
21. Chuang, C. H.; Chuang, K. H.; Wang, H. E.; Roffler, S. R.; Shiea, 
J. T.; Tzou, S. C.; Cheng, T. C.; Kao, C. H.; Wu, S. Y.; Tseng, W. L.; 
Cheng, C. M.; Hou, M. F.; Wang, J. M.; and Cheng, T. L. In vivo 
positron emission tomography imaging of protease activity by genera-
tion of a hydrophobic product from a noninhibitory protease substrate, 
Clin. Cancer Res. 2012 18, 238-247. 
22. Atkinson, J. M.; Falconer, R. A.; Edwards, D. R.; Pennington, C. 
J.; Siller, C. S.; Shnyder, S. D.; Bibby, M. C.; Patterson, L. H.; 
Loadman, P. M.; and Gill, J. H. Development of a novel tumor-
targeted vascular disrupting agent activated by membrane-type matrix 
metalloproteinases, Cancer Res. 2010 70, 6902-6912. 
23. Vandooren, J.; Opdenakker, G.; Loadman, P. M.; and Edwards, D. 
R. Proteases in cancer drug delivery, Adv. Drug Deliv. Rev. 2016 97, 
144-155. 
24. Choi, K. Y.; Swierczewska, M.; Lee, S.; and Chen, X.  Protease-
activated drug development, Theranostics 2012 2, 156-178. 
25. Ansari, C.; Tikhomirov, G. A.; Hong, S. H.; Falconer, R. A.; 
Loadman, P. M.; Gill, J. H.; Castaneda, R.; Hazard, F. K.; Tong, L.; 
Lenkov, O. D.; Felsher, D. W.; Rao, J.; and Daldrup-Link, H. E. De-
velopment of novel tumor-targeted theranostic nanoparticles activated 
by membrane-type matrix metalloproteinases for combined cancer 
magnetic resonance imaging and therapy, Small 2014 10, 566-575, 
417. 
26. Wang, Y.; Pu, L.; Li, Z.; Hu, X.; and Jiang, L. Hypoxia-inducible 
factor-1alpha gene expression and apoptosis in ischemia-reperfusion 
injury: a rat model of early-stage pressure ulcer, Nurs. Res. 2016  65, 
35-46. 
27. Huggins, D. J.; Sherman, W.; and Tidor, B. Rational approaches 
to improving selectivity in drug design, J. Med. Chem. 2012 55, 1424-
1444. 
28. Rowsell, S.; Hawtin, P.; Minshull, C. A.; Jepson, H.; Brockbank, 
S. M.; Barratt, D. G.; Slater, A. M.; McPheat, W. L.; Waterson, D.; 
Henney, A. M.; and Pauptit, R. A. Crystal structure of human MMP9 
in complex with a reverse hydroxamate inhibitor, J. Mol. Biol. 2002 
319, 173-181. 
Page 6 of 12
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 7 
 
29. Dhanaraj, V.; Ye, Q-Z.; Johnson, LL.; Hupe, DJ.; Ortwine, DF.; 
Dunbar, JB.; Rubin, JR.; Pavlovsky, A.; Humblet, C.; and Blundell, 
TL. X-ray structure of gelatinase A  catalytic domain complexed with 
a hydroxamate inhibitor, Croat. Chem. Acta 1999 72, 575-591. 
30. Fernandez-Catalan, C.; Bode, W.; Huber, R.; Turk, D.; Calvete, 
JJ.; Lichte, A.; Tschesche, H., and Maskos, K. Crystal structure of the 
complex formed by the membrane type 1-matrix metalloproteinase 
with the tissue inhibitor of metalloproteinase-2, the soluble progelati-
nase A receptor, Embo J. 1998 17, 5238-5248. 
31. Maskos, K. Crystal structures of MMPs in complex with physio-
logical and pharmacological inhibitors, Biochimie 2005 87, 249-263. 
32. Bickett, D. M.; Green, M. D.; Berman, J.; Dezube, M.; Howe, A. 
S.; Brown, P. J.; Roth, J. T.; and McGeehan, G. M. A high throughput 
fluorogenic substrate for interstitial collagenase (MMP-1) and gelati-
nase (MMP-9), Anal. Biochem 1993. 212, 58-64. 
33. Albright, C. F.; Graciani, N.; Han, W.; Yue, E.; Stein, R., Lai, Z.; 
Diamond, M.; Dowling, R.; Grimminger, L.; Zhang, S. Y.; Behrens, 
D.; Musselman, A.; Bruckner, R.; Zhang, M.; Jiang, X.; Hu, D.; 
Higley, A.; Dimeo, S.; Rafalski, M.; Mandlekar, S.; Car, B.; Yeleswa-
ram, S.; Stern, A.; Copeland, R. A.; Combs, A.; Seitz, S. P.; Trainor, 
G. L.; Taub, R.; Huang, P.; and Oliff, A. Matrix metalloproteinase-
activated doxorubicin prodrugs inhibit HT1080 xenograft growth 
better than doxorubicin with less toxicity, Mol. Cancer Ther. 2005 4, 
751-760. 
34. Hu, Z.; Jiang, X.; Albright, C. F.; Graciani, N.; Yue, E.; Zhang, 
M.; Zhang, S. Y.; Bruckner, R.; Diamond, M.; Dowling, R.; Rafalski, 
M.; Yeleswaram, S.; Trainor, G. L.; Seitz, S. P.; and Han, W. Discov-
ery of matrix metalloproteases selective and activated peptide-
doxorubicin prodrugs as anti-tumor agents, Bioorg. Med. Chem. Lett. 
2010 20, 853-856. 
35. Atkinson, J. M.; Falconer, R. A.; Edwards, D. R.; Pennington, C. 
J.; Siller, C. S.; Shnyder, S. D.; Bibby, M. C.; Patterson, L. H.; 
Loadman, P. M.; and Gill, J. H. Development of a novel tumor-
targeted vascular disrupting agent activated by MT-MMPs, Cancer 
Res. 2010 17, 6902-6912. 
36. Kridel, SJ.; Sawai, H.; Ratnikov, BI.; Chen, EI.; Li, W.; Godzik, 
A.; Strongin, AY.; and Smith, JW. A unique substrate binding mode 
discriminates membrane type-I matrix metalloproteinase from other 
matrix metalloproteinases. J. Biol. Chem. 2002 277, 23788-23793. 
37. McClellan, M.; Benner, J.; Schilsky, R.; Epstein, D.; Woosley, R.; 
Friend, S.; Sidransky, D.; Geoghegan, C.; and Kessler, D. An acceler-
ated pathway for targeted cancer therapies, Nat. Rev. Drug Discov. 
2011 10, 79-80. 
38. Santiskulvong, C.; and Rozengurt, E. Galardin (GM6001), a 
broad-spectrum matrix metalloproteinase inhibitor, blocks bombesin- 
and LPA-induced EGF receptor tranactivation and DNA synthesis in 
rat-1 cells. Exp. Cell Res. 2003 290, 437-446. 
39. Wang, H.; Xu, T.; Jiang, Y.; Xu, H.; Yan, Y.; Fu, D.; and Chen, J. 
The challenges and the promise of molecular targeted therapy in ma-
lignant gliomas, Neoplasia 2015 17, 239-255. 
40. Vartak, D. G.; and Gemeinhart, R. A. Matrix metalloproteases: 
underutilized targets for drug delivery, J. Drug Target 2007 15, 1-20. 
41. Cathcart, J.; Pulkoski-Gross, A.; and Cao, J. Targeting matrix 
metalloproteinases in cancer: bringing new life to old ideas, Genes 
Dis. 2015 2, 26-34. 
 
 
For Table of Contents Only 
 
                                                                                                                             
 
 
 
 
Page 7 of 12
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
 
Figure 1. (Top) Stereo view of the docked complexes of 1 sub-strate and the catalytic domain of human 
MMP-2 (PDB ID: 1QIB) and MMP-9 (PDB ID: 1GKC). The MMP-substrate docked complexes are merged with 
zinc as the same point of view. MMP-2 structure is shown in red, zinc as purple and 1 substrate (white 
sticks) docked within MMP-2 active site. MMP-9 is shown in grey, zinc as green and 1 substrate (thin green 
sticks) docked within its active site. (Bottom) Schematic representation of 1: active site binding interaction 
in human MMP-2 and MMP-9. MMP-2 and MMP-9 enzyme binding pockets are shown in red and green 
respectively. Substrate chemical structure and its scissile bond is shown in black. The zinc ion is indicated in 
blue.  
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Figure 2. Schematic representation of the cleavage of 1 substrate by recombinant MMP-2 and MMP-9 
enzymes at Gly-Cys(Me).  
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Figure 3. Schematic representation of the cleavage of 2 by re-combinant MMP-2 and MMP-9 enzymes at the 
Gly-Ser(O-Bn) bond.  
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Figure 4. (Left) Stereo view of docked complexes of 3 (white sticks), catalytic domain of human MMP-2 (PDB 
ID: 1QIB) (Red) and MMP-9 (PDB ID: 1GKC) (Green). Catalytic and structural zinc ions are shown as purple 
spheres and active-site cleft residues (αβ-helix loop and the specificity loop) are shown as green. (Right) 
Schematic representation of 3 substrate: active site binding interaction in MMP-2 and MMP-9, are shown in 
red and green respectively. Substrate chemical structure and its scissile bond is shown in black and zinc ion 
coordinated by histidine is indicated in blue.  
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Figure 5. Therapeutic activity of 3 against human cancer. A) Expression of MMP-2 and MMP-9 mRNA in the 
U87-MG glio-ma cell line; B) MMP-activity in the U87-MG cell line, as demonstrated by activation of 1 
substrate Dnp-Pro-β-cyclohexyl-Ala-Gly-Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH2; C) Cytotoxicity of 
doxorubicin, Leu-Dox and 3 against U87-MG cell line. MMP-selective activation of 3 in the presence of a pan-
MMP inhibitor (Ilomastat).  
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